Pretreatment of therapeutic cells with poly(ADP-ribose) polymerase inhibitor enhances their efficacy in an in vitro model of cell-based therapy in myocardial infarct
Open Access
- 16 November 2012
- journal article
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 31 (1) , 26-32
Abstract
The potential of cell-based therapies in diseases involving ischemia-reperfusion is greatly hampered by the excessive loss of administered cells in the harsh and oxidative environment where these cells are supposed to act. Therefore, we investigated if inhibition of poly(ADP-ribose) polymerase (PARP) in the therapeutically added cells would lead to their increased viability and, subsequently, to an enhanced effect in an in vitro simulated ischemia-reperfusion (I-R) setting. Ischemic conditions were simulated by oxygen and glucose deprivation for 160 min using H9c2 rat cardiomyoblast cells. After 30 min of reperfusion, these cells received 4 types of treatments: no added cells (I-R model), fluorescently labeled (Vybrant DiD) therapeutic H9c2 cells with vehicle (H9c2) or PARP inhibitor (10 µM or 100 µM PJ34) pretreatment. We assessed viability (live, apoptotic and necrotic) of both 'postischemic' and therapeutic cells with flow cytometric analysis using calcein-AM/ethidium homodimer-2 fluorescent staining after 24 h of co-culture. Further measurements on necrosis and metabolic activity were performed using lactate dehydrogenase (LDH) release and resazurin based assays. The percentage of surviving therapeutic cells increased significantly with PARP inhibition (untreated, 52.02±5.01%; 10 µM PJ34, 63.38±4.50%; 100 µM PJ34, 64.99±3.47%). The percentage of necrotic cells decreased in a similar manner (untreated, 37.23±4.40%; 10 µM PJ34, 26.83±3.49%; 100 µM PJ34, 24.96±2.43%). Notably, the survival of the cells that suffered I-R injury was also significantly higher when treated with PARP-inhibited therapeutic cells (I-R model, 36.44±5.05%; H9c2, 42.81±5.11%; 10 µM PJ34, 52.07±5.80%; 100 µM PJ34, 54.95±5.55%), while necrosis was inhibited (I-R model, 43.64±4.00%; H9c2, 37.29±4.55%; 10 µM PJ34, 30.18±4.60%; 100 µM PJ34, 25.52±3.47%). In subsequent experiments, PARP inhibition decreased LDH-release of the observed combined cell population and enhanced the metabolic activity. Thus, our results suggest that pretreating the therapeutically added cells with a PARP inhibitor could be beneficial in the setting of cell-based therapies.Keywords
This publication has 41 references indexed in Scilit:
- Bone Marrow Stem Cells Prevent Left Ventricular Remodeling of Ischemic Heart Through Paracrine SignalingCirculation Research, 2006
- Mediation of cell death by poly(ADP-ribose) polymerase-1Pharmacological Research, 2005
- Effect of poly(ADP-ribosyl)ation inhibitors on the genotoxic effects of the boron neutron capture reactionMutation Research - Genetic Toxicology and Environmental Mutagenesis, 2005
- Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitorsNature Reviews Drug Discovery, 2005
- Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted heartsNature Medicine, 2003
- The Therapeutic Potential of Poly(ADP-Ribose) Polymerase InhibitorsPharmacological Reviews, 2002
- Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1Nature Cell Biology, 2001
- Inosine Reduces Systemic Inflammation and Improves Survival in Septic Shock Induced by Cecal Ligation and PunctureAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Physiology and pathophysiology of poly(ADP‐ribosyl)ation *BioEssays, 2001
- Properties of a clonal muscle cell line from rat heartExperimental Cell Research, 1976